ABOUT ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Section A, individuals will acquire distinctive doses and schedules of oral ABBV-744 tablet to recognize Protected dosing regimen. Added individuals will probably be enrolled at the discovered monotherapy dosign routine. In Phase B, individuals will receive oral ruxolitinib and ABBV-744 is going to be provided as "add-on" therapy. In Section C,